DCGI permission for Glenmark to test its novel anti-tumour drug
GRC 54276 is one of the many novel molecules from Glenmark’s in-house Innovative Medicines Group, headed by Dr. Nikhil Amin, chief scientific officer, specialising in the development of novel molecular entities for critical unmet medical needs.